CN112884530A - Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group - Google Patents
Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group Download PDFInfo
- Publication number
- CN112884530A CN112884530A CN202110316200.8A CN202110316200A CN112884530A CN 112884530 A CN112884530 A CN 112884530A CN 202110316200 A CN202110316200 A CN 202110316200A CN 112884530 A CN112884530 A CN 112884530A
- Authority
- CN
- China
- Prior art keywords
- medicine
- same
- platform
- gpo
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0201—Market modelling; Market analysis; Collecting market data
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0201—Market modelling; Market analysis; Collecting market data
- G06Q30/0206—Price or cost determination based on market factors
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
Landscapes
- Business, Economics & Management (AREA)
- Engineering & Computer Science (AREA)
- Strategic Management (AREA)
- Finance (AREA)
- Development Economics (AREA)
- Accounting & Taxation (AREA)
- Entrepreneurship & Innovation (AREA)
- Economics (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- General Business, Economics & Management (AREA)
- Data Mining & Analysis (AREA)
- Marketing (AREA)
- Health & Medical Sciences (AREA)
- Game Theory and Decision Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
The invention discloses a method for measuring and calculating the purchase price reduction amplitude and the saved amount of a medicine group, which comprises two parts, wherein the first part is to perform matching grouping on the medicines of a platform (to be measured) and GPO medicines, and the second part is to perform price reduction amplitude and the saved amount measurement and calculation on the medicines; the invention realizes the conversion of different platform medicines through the catalog matching, realizes the conversion of different platform medicine purchase quantities through the daily average dosage, compares the price of the medicines through the daily average cost and calculates the whole medicine cost; the method can predict the total purchase amount of the original purchasing platform medicine converted into the group purchased medicine before online and the total purchase amount of the original purchasing platform medicine converted into the group purchased medicine after online measurement, thereby measuring and calculating the amount saved by group purchasing and comparing the total price reduction range of the original purchasing platform and the group purchased medicine, and making data support for medical insurance decision.
Description
Technical Field
The invention belongs to the technical field of evaluating price reduction of medicines, and particularly relates to a method for measuring and calculating the purchase reduction range and the saved amount of a medicine group.
Background
The traditional method for evaluating the price reduction of the medicine is to reduce the price of the medicine by the unit price of the same product, the medicines purchased in different time periods belong to the medicines with the same universal name and the same catalogue dosage form, but the medicines with different production enterprises, different dosage forms or different specifications cannot be subjected to the reduction statistics, so the measured reduction is incomplete, and the reduction range of the integral purchase amount of the medicine and the total saved amount cannot be counted.
The GPO platform is used for perfecting centralized purchasing work of medicines in public hospitals, reducing the deficiency and high price of the medicines, lightening the burden of medical expenses of citizens and promoting the healthy development of the medical industry. After group purchase, firstly, converting the medicines of the original purchase platform to a GPO platform, not converting the medicines of different products, but converting the medicines of the same universal name, the same catalogue dosage form and the same quality level; secondly, the overall reduction is not only related to price but also related to purchase quantity, the purchase quantity is deviated to a variety with large reduction, and the overall amount can be saved and the reduction is larger; thirdly, the decrease of the group purchasing is evaluated as the decrease of the total purchasing amount rather than the decrease of the unit price, so that the conversion of the purchasing amount is carried out on the medicines with the same general name, the same catalogue dosage form and the same quality level through catalogue matching, and the decrease of the total purchasing amount is calculated.
The difficulty is that the drug data of different purchasing platforms are expressed differently, and the drug data needs to be standardized; matching the medicines with different platforms, same universal name, same catalogue dosage form and same quality level to screen out the medicines capable of converting the purchase quantity among different production enterprises, different dosage forms or medicines with different specifications; and thirdly, reasonable amount conversion is carried out on products of different production enterprises, different dosage forms and even different specifications by using the number of days for taking medicine, and the daily medicine amount of the medicine is combined, so that the change of the total purchase amount of the two platforms caused by the change of the medicine price is calculated by taking the amount of the medicine in a certain period as a reference.
In order to find out problems in the process of executing group purchasing, calculate the amount of money actually saved by group purchasing and make data support for medical insurance decision, a method for calculating the price reduction range and the amount saved by group purchasing is provided.
Disclosure of Invention
The invention aims to provide a method for measuring and calculating the price reduction range and the saved amount of the group purchasing of medicines, which is used for finding out the problems in the process of executing the group purchasing, measuring and calculating the amount of money which can be actually saved by the group purchasing and making data support for medical insurance decisions.
In order to achieve the purpose, the invention provides the following technical scheme: a method for measuring and calculating the purchase price reduction amplitude and the saved amount of a medicine group comprises two parts, wherein the first part is to perform matching grouping on a platform A (to be measured) medicine and a GPO medicine, and the second part is to perform price reduction amplitude and the saved amount measurement and calculation on the medicine; the measuring and calculating method comprises the following steps:
the method comprises the following steps: before the GPO platform is on-line, the amplitude is reduced and the amount can be saved is predicted: under the premise that the sales quantity of the platform A is not changed, the method calculates and calculates the purchase amount of each grouped variety for the price of the hospital by group purchase, further calculates and calculates the theoretical total sales amount of all the purchase groups, compares the theoretical total sales amount with the total medicine purchase amount of the platform A, and calculates the price reduction range;
step two: and (3) measuring and calculating the actual amplitude reduction and the amount saved after the GPO platform is on line: determining theoretical total purchase amount of all varieties of the A platform medical institution according to daily use amount of each medicine group purchased by the A platform on the original platform on the premise of determining actual purchase amount of the GPO platform, and calculating price reduction amplitude by comparing the total purchase amount of the medicines actually purchased by the A platform on the GPO platform with the theoretical total purchase amount;
step three: receiving the calculated data through a data receiving module, and importing the data into a file system for processing;
step four: and the processed data is counted and called through a counting module.
As a preferred technical scheme of the invention, the matching of the A platform medicine and the GPO medicine is as follows:
matching the common names of the two platforms of medicines;
secondly, matching the platform A medicine and the GPO medicine with the same common name and the GPO medicine with the same catalog dosage form under the common name;
thirdly, matching the platform A medicine and the GPO medicine with the same common name and the same catalogue dosage form in quality level with the GPO medicine under the same common name and the same catalogue dosage form;
fourthly, matching the A platform medicine and the GPO medicine with the same common name, the same catalogue formulation and the same quality level, wherein the attributes comprise the varieties of sugar-free, musk and bezoar, and the A platform medicine and the GPO medicine are matched with the GPO medicine with the same common name, the same catalogue formulation and the same quality level;
fifthly, matching the large-capacity basic infusion in the same-generic-name same-catalogue medicament form and same-quality-level medicament of the A platform medicament and the GPO medicament with an injection containing a refill, a specially-filled and pre-filled type (pre-filled and sealed) injector packing material under the same-generic-name same-catalogue medicament form and same-quality-level packing material;
sixthly, matching the attributes of the A platform medicine and the GPO medicine, matching the packing material, and matching the A platform medicine and the GPO medicine in specification without considering the attributes and the packing material of the medicine with the same general name, the same catalogue dosage form and the same quality level;
seventhly, matching the attributes of the A platform medicine and the GPO medicine, matching packing materials, matching the medicines with the same general name, the same catalogue dosage form and the same quality level without considering the attributes and the packing materials, and matching small dosage forms after the medicines are matched with the GPO medicine in specification;
and eighthly, matching the attributes of the A platform medicine and the GPO medicine, matching the packaging material, and matching the medicine with the same general name, the same catalogue dosage form, the same quality level, the same specification and the same small dosage form without considering the attributes and the packaging material with the GPO medicine for the medicine production enterprises.
As a preferred embodiment of the present invention, the distinction between the attribute containing sugar and the attribute not containing sugar (referring to sucrose only) is divided into different groups; the calculus bovis and Moschus contained in the composition are divided into three groups according to nature, cultivation (including in vitro cultivation), and artificial cultivation.
As a preferred technical solution of the present invention, an a-platform drug that can be matched to the same GPO drug is regarded as the same group, and corresponds to the GPO drug, and in the group matching process, preferential matching is performed in the following order: firstly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and the same production enterprises, and secondly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and different production enterprises; thirdly, matching medicines with the same universal name, the same catalog dosage form and the same specification and different small dosage forms; matching with medicines with the same general name, the same catalog dosage form and the same small dosage form and different specifications again; matching the medicines with the same universal name, the same catalog dosage form, different small dosage forms and different specifications.
As a preferred technical scheme of the invention, the price reduction amplitude and the amount which can be saved are measured and calculated: before the online process, a Rad price index method is used for predicting the amplitude reduction and the amount of money saved of GPO if the medicine of the A platform is purchased on a GPO platform, and after the online process is finished, a Pascal price index method is used for measuring and calculating the actual amplitude reduction and the actual amount of money saved of the medicine purchased by the GPO.
In a preferred embodiment of the present invention, the larch price index is an index in which a quantity in a basic period is used as a weight, and a purchase quantity in the same amount is fixed in the basic period, and a change in the total amount is compared to reflect a change in the price.
In a preferred embodiment of the present invention, the parr price index is an index in which the amount in the report period is weighted, the purchase amount in the same amount is fixed in the report period, and the change of the total amount is compared to reflect the change of the price.
As a preferred technical solution of the present invention, the mobile terminal further includes a logic processing module, and the logic processing module is configured to obtain valid data according to a receiving condition of the data, where the valid data includes: determining whether at least one of data loss and data duplication occurs.
As a preferred technical solution of the present invention, the file system further includes an update module, and the update module is configured to update the file system.
Compared with the prior art, the invention has the beneficial effects that:
(1) the conversion of different platforms of medicines is realized through catalog matching, the conversion of different platforms of medicine purchase quantities is realized through daily average dosage, the price of the medicines is compared through daily average cost, and the whole medicine cost is calculated;
(2) the total purchase amount of the original purchasing platform medicine is converted into the total purchase amount of the group purchased medicine before online measurement and the total purchase amount of the original purchasing platform medicine is converted into the group purchased medicine after online measurement can be predicted, so that the amount saved by group purchasing is measured and calculated, and the total price reduction amplitude of the group purchased medicine is compared with the original purchasing platform; the problem in the process of executing group purchasing can be found out by comparing the price reduction range and the saved amount before and after group purchasing, and the amount which can be saved in the actual group purchasing can be measured and calculated, so that data support is made for medical insurance decision;
(3) the modular design is beneficial to reducing the influence of redundant data, improving the accuracy of data processing, reducing the time consumption of measurement and calculation, improving the efficiency of measurement and calculation and having good market popularization value.
Drawings
FIG. 1 is a directory matching principle diagram of the present invention;
FIG. 2 is a diagram of the prediction of the amplitude reduction and the amount of money saved before the GPO platform of the present invention is on-line;
FIG. 3 is a diagram of the actual amplitude reduction and the amount saved calculation after the GPO platform of the present invention is on-line;
FIG. 4 is a flowchart of a method of measurement and calculation according to the present invention.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Referring to fig. 1, fig. 2, fig. 3, and fig. 4, the present invention provides a technical solution: a method for measuring and calculating the purchase price reduction amplitude and the saved amount of a medicine group comprises two parts, wherein the first part is to perform matching grouping on a platform A (to be measured) medicine and a GPO medicine, and the second part is to perform price reduction amplitude and the saved amount measurement and calculation on the medicine; the method comprises the following measuring and calculating steps:
the method comprises the following steps: before the GPO platform is on-line, the amplitude is reduced and the amount can be saved is predicted: under the premise that the sales quantity of the platform A is not changed, the method calculates and calculates the purchase amount of each grouped variety for the price of the hospital by group purchase, further calculates and calculates the theoretical total sales amount of all the purchase groups, compares the theoretical total sales amount with the total medicine purchase amount of the platform A, and calculates the price reduction range; in order to facilitate the conversion of the medication quantity of different specifications under the same universal name and the same catalog dosage form in the catalog into the medication quantity of a transaction product, the concept of medication days is introduced, the medication days refer to the medication days of the product calculated according to the recommended daily dosage under the existing medication quantity, and the algorithm carries out reasonable quantity conversion on the products of different specifications and even different dosage forms; calculating the formula:
R＝∑[[∑(M0/T0)]*T1*P1]/∑S0*100％-100％
note: r is the price reduction range
M0Sales number of A platform Hospital drug catalog single products
T0Daily average dosage of a single product of a medication list of a platform hospital
T1Daily average consumption of purchased and delivered products by group
P1Price of procured and delivered products for hospital
S0A platform hospital pharmacy catalog each group actual sales amount;
1. calculating the total days of medication of the same group
According to the purchase quantity (M) of each product in the A platform medicine data0) The daily average dosage (T)0) Calculating the total days of administration (D)0)。
Calculating the formula: d0＝∑In the same group(M0/T0)
Note: d0: total days for same group
2. Calculating theoretical purchasing quantity of group purchasing in each group
Sum of days for the same group using this variety (D)0) Multiplied by the daily average dosage (T) of the matched GPO product1) Obtaining the theoretical purchasing quantity (M) corresponding to the group purchasing transaction group1)
Calculating the formula: m1＝D0*T1
Note: m1: theoretical number of bought per group
3. Calculating theoretical purchasing amount of each group purchasing
Purchasing theoretical purchasing quantity (M) by each group1) Procurement of hospital price (P) by Shenzhen market cluster1) Calculating the theoretical purchasing amount (S) of the group of group purchasing1)。
Calculating the formula: s1＝M1*P1
Note: s1: theoretical amount of purchase per group
4. Calculating the comprehensive amplitude reduction
Actual purchase amount of the drug according to the same group A platform (S)0) And theoretical purchase amount (S) of each group1) And calculating the price reduction range (R) of the group purchase catalogue deal variety relative to the A platform medicine purchase data.
The calculation formula is as follows: r ═ Σ S1/∑S0*100％-100％
Note: r: the reduction of the group purchase transaction varieties relative to the A platform medicine purchase data is 5, and the saved amount is calculated
According to the actual purchase amount (Sigma S) of the medicine of the platform A0) And theoretical purchase amount (Sigma S) of group purchase1) Calculating the amount of money (S) that can be saved by purchasing the medicine using the group while maintaining the number of medicines used on the A platforma)。
The calculation formula is as follows: sa＝∑S0-∑S1
Note: sa: the group purchase is expected to save money.
Step two: and (3) measuring and calculating the actual amplitude reduction and the amount saved after the GPO platform is on line: determining theoretical total purchase amount of all varieties of the A platform medical institution according to daily use amount of each medicine group purchased by the A platform on the original platform on the premise of determining actual purchase amount of the GPO platform, and calculating price reduction amplitude by comparing the total purchase amount of the medicines actually purchased by the A platform on the GPO platform with the theoretical total purchase amount; in order to calculate the daily drug amounts of different specifications under the same universal name and the same catalog dosage form, the concept of 'medication days' is specially introduced, wherein the 'medication days' refers to the medication days of the product calculated according to the recommended daily dosage under the existing medication quantity, and the algorithm carries out reasonable quantity conversion on the products of different specifications and even different dosage forms; calculating the formula:
R＝∑S1/∑[S0/∑(M0/T0)*(M1/T1)]*100％-100％
note: r is the price reduction range
M0The purchasing quantity of each product purchased by the A platform on the original platform
M1The purchase quantity of each product actually purchased by the A platform at the GPO
T0Average daily consumption of each product purchased by the A platform on the original platform
T1Average daily usage of each product actually purchased by the A platform at the GPO
S0Theoretical purchase amount of each group of products purchased by the A platform on the original platform
S1A platform actually collects each group of products actually purchased by GPOAnd (6) purchasing money.
1. Calculating the total number of days for the same group of medicine using the original purchasing platform of the A platform
According to the purchase quantity (M) of each product in the original purchase platform medicine data of the A platform0) The daily average dosage (T)0) Calculating the number of days (i.e. M) taken by the product0/T0) And further calculating the total days of the same group (D)0)。
Calculating the formula: d0＝∑In the same group(M0/T0)
Note: d0: sum of days for medicine taking of same group of original purchasing platform of A platform
Similarly, the actual purchase quantity (M) of the products matched with the same group on the GPO platform according to the A platform1) The daily average dosage (T)1) Calculating the number of days (D) taken1)。
Calculating the formula: d1＝M1/T1
Note: d1: days for taking medicine of GPO actual purchased product by platform A
2. Calculating the amount of daily medicine in each group
Using the original purchasing platform of the A platform to purchase the amount of money of each group (S)0) Divided by the sum of days taken in the same group (D)0) Obtaining the daily medication amount (P) of the same group of the original purchasing platform of the platform A0)。
Calculating the formula: p0＝S0/D0
Note: p0: daily amount of medicine for the same group of original platform purchasing platform of platform A
3. Calculating theoretical purchase amount of each group
Days of drug administration per product actually purchased at GPO with platform A (D)1) Multiplying the daily drug amount (P) of the same group of drugs by the matched A platform original purchasing platform0) Obtaining each group of theoretical purchase amount (S)R)。
Calculating the formula:
SR＝D1*P0
SR: theoretical purchase amount of medicines in same group of original purchase platform of platform A
4. Calculating the comprehensive amplitude reduction
Actual purchase amount (S) at GPO according to platform A1) And theoretical purchase amount (S) of same group of medicinesR) Calculating the price reduction amplitude (R) of the total sum of the medicines actually purchased by the platform A in the GPO relative to the theoretical total sum of the medicines actually purchased by the original purchasing platform of the platform A; the calculation formula is as follows:
R＝∑S1/∑SR*100％-100％
r: the price reduction range of the total amount of the medicines actually purchased by the platform A in GPO relative to the original purchase amount of the platform A
4. Calculating the actual savings
Actual purchase amount (S) at GPO according to platform A1) And the original platform theoretical purchase amount (S) calculated according to the original purchase priceR) Calculating the amount of money (S) that the group purchased medicine can actually save while maintaining the same actual medicine purchase amount of the GPO platform Aa)。
The calculation formula is as follows: sa＝∑SR-∑S1
Note: sa: the actual amount of money saved by group purchase
Attached:
daily average dosage calculation
Firstly, calculating the average daily dose (DDD/product dose) according to the limited daily dose (ATC/DDD) of the WHO official network
Such as: [ amitriptyline | oral ] administration
DDD: 75mg, pharmaceutical size: 25mg of
The daily average dosage is 75 mg/25 mg/3 tablets
(ii) if the WHO does not have the limited daily dose (ATC/DDD), calculating the daily average dose (the daily minimum dose + the daily maximum dose)/2 according to the pharmaceutical instruction (usage dose)
Wherein: the minimum daily dose is the minimum daily number of times of administration and the minimum daily dose of the drug
Maximum daily dose is the maximum daily dose and maximum daily dose
Third, if the WHO does not have the limited daily dose (ATC/DDD), the instructions (usage and dosage) are unified and converted into the price of per gram/milligram/milliliter and the like, namely the unit comparable price, and the calculation of the daily average cost is carried out.
There are two calculation methods for the average daily cost:
the average daily cost is equal to the average daily dosage and the minimum unit price of the preparation
② the daily average charge is medicine purchase sum and medicine using days
Wherein the administration days are the minimum preparation amount divided by the daily average dosage.
Step three: receiving the calculated data through a data receiving module, and importing the data into a file system for processing;
step four: and the processed data is counted and called through a counting module.
In this embodiment, preferably, the a-platform medicine is matched with the GPO medicine:
matching the common names of the two platforms of medicines, wherein if the common name of the A platform of medicines is not matched with the GPO medicine, the A platform of medicines is a non-GPO catalog medicine;
secondly, matching the platform A medicine and the GPO medicine with the same common name with the catalog dosage form under the same common name, and if the catalog dosage forms are different, determining that the platform A medicine is a non-GPO catalog medicine;
thirdly, matching the A platform medicine and the GPO medicine with the same common name and the same catalogue dosage form in quality level under the condition of the same common name and the same catalogue dosage form with the GPO medicine, and if the quality level is different, mismatching the A platform medicine and the GPO medicine;
fourthly, the A platform medicine and the GPO medicine have the same common name, the same catalogue formulation and the same quality level, the attributes of the A platform medicine and the GPO medicine contain varieties of sugar-free, musk and bezoar, the A platform medicine and the GPO medicine are matched with the GPO medicine under the same quality level of the same common name and the same catalogue formulation, if the attributes of the A platform medicine and the GPO medicine are different, the A platform medicine and the GPO medicine are not matched (note that the attribute contains sugar and does not contain sugar (only refers to sucrose) are divided into different groups, and the medicine containing bezoar and musk is divided into three different groups according to nature, cultivation (including in vitro cultivation);
and fifthly, matching the high-capacity basic infusion in the same-common-name, same-catalogue-dosage-form and same-quality-level medicines of the A-platform medicines and the GPO medicines with the injection containing a refill, specially-charged and pre-charged (pre-filled and sealed) injector packing materials in the same-common-name and same-catalogue-dosage-form and the GPO medicines, and if the packing materials are different, mismatching the A-platform medicines and the GPO medicines (filling: the packing material refill, the specially-charged and pre-charged (pre-filled and sealed) injectors are divided into different groups, and equally dividing high-capacity basic infusion glass bottles, plastic bottles, soft bags, upright soft bags and soft bag double valves into different groups).
Sixthly, matching the attributes of the A platform medicine and the GPO medicine, matching the packing material, matching the specifications of the A platform medicine and the GPO medicine without considering the attributes and the packing material of the same general name, same catalogue dosage form and same quality level, matching the A platform medicine and the GPO medicine in small dosage forms if the specifications are different, and matching the A platform medicine and the GPO medicine (the general name and the catalogue dosage form are consistent) if the small dosage forms are different; if the small dosage forms are the same, the A platform medicine is matched with the GPO medicine (the common name, the catalogue dosage form and the small dosage form are consistent);
seventhly, matching the attributes of the A platform medicine and the GPO medicine, matching packing materials, matching the A platform medicine with the GPO medicine in specifications without considering the attributes and the packing materials, matching the A platform medicine with the GPO medicine in specifications, matching the A platform medicine with the GPO medicine in small dosage forms if the A platform medicine is the same as the GPO medicine in general name, the same catalog dosage form and the same quality level, and matching the A platform medicine with the GPO medicine (the general name, the catalog dosage form and the specification are consistent) if the A platform medicine is different from the GPO medicine; if the small dosage forms are the same, matching the A platform medicine with the GPO medicine by the medicine manufacturing enterprises, and if the two platforms of medicine manufacturing enterprises are different, matching the A platform medicine with the GPO medicine (the product specifications are consistent); if the two platform drug manufacturing enterprises are the same, the A platform drug is matched with the GPO drug (same product).
In this embodiment, preferably, the a platform drugs that can be matched to the same GPO drug are regarded as the same group, and correspond to the GPO drug, and in the group matching process, the preferential matching is performed in the following order: firstly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and the same production enterprises, and secondly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and different production enterprises; thirdly, matching medicines with the same universal name, the same catalog dosage form and the same specification and different small dosage forms; matching with medicines with the same general name, the same catalog dosage form and the same small dosage form and different specifications again; matching the medicines with the same universal name, the same catalog dosage form, different small dosage forms and different specifications.
In this embodiment, preferably, the price reduction range and the amount that can be saved are measured: before the online process, a Rad price index method is used for predicting the amplitude reduction and the amount of money saved of GPO if the medicine of the A platform is purchased on a GPO platform, and after the online process is finished, a Pascal price index method is used for measuring and calculating the actual amplitude reduction and the actual amount of money saved of the medicine purchased by the GPO.
In this embodiment, preferably, the larch price index is an index taking the amount in the base period as the weight, the purchase amount in the same amount is fixed in the base period, and the change of the total amount is compared to reflect the change of the price; the formula is as follows:
∑P1Q0total amount of report period calculated by number of base periods
∑P0Q0Total amount of money in the base period
∑P1Q0/∑P0Q0The total amount is increased or decreased by a percentage due to price changes.
In this embodiment, preferably, the parr price index is an index taking the amount in the report period as a weight, the purchase amount in the same amount is fixed in the report period, and the change of the total amount is compared to reflect the change of the price; the formula is as follows:
∑P1Q1total amount of money in report period
∑P0Q1Total amount of funds based on the number of reported sessions
∑P1Q1/∑P0Q1The total amount is increased or decreased by a percentage due to price changes.
Catalog dosage form: the catalog dosage forms integrated with the pharmaceutical dosage forms according to the procurement catalog dosage form integration rules (trial) of the pharmaceutical group of the public hospitals in city are shown in the following table:
in this embodiment, it is preferable that the data processing apparatus further includes a logic processing module, and the logic processing module is configured to obtain valid data according to a receiving condition of the data, where the valid data includes: and judging whether at least one of data loss and data repetition occurs or not, which is beneficial to reducing the influence of redundant data and improving the accuracy of data processing.
In this embodiment, preferably, the file system further includes an update module, and the update module is configured to update the file system.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (9)
1. A method for measuring and calculating the purchasing price reduction range and the saved amount of a medicine group is characterized by comprising the following steps: the method comprises two major components, wherein the first component is used for matching and grouping A platform (to be measured) medicines and GPO medicines, and the second component is used for reducing price and measuring and calculating the amount of money saved; the measuring and calculating method comprises the following steps:
the method comprises the following steps: before the GPO platform is on-line, the amplitude is reduced and the amount can be saved is predicted: under the premise that the sales quantity of the platform A is not changed, the method calculates and calculates the purchase amount of each grouped variety for the price of the hospital by group purchase, further calculates and calculates the theoretical total sales amount of all the purchase groups, compares the theoretical total sales amount with the total medicine purchase amount of the platform A, and calculates the price reduction range;
step two: and (3) measuring and calculating the actual amplitude reduction and the amount saved after the GPO platform is on line: determining theoretical total purchase amount of all varieties of the A platform medical institution according to daily use amount of each medicine group purchased by the A platform on the original platform on the premise of determining actual purchase amount of the GPO platform, and calculating price reduction amplitude by comparing the total purchase amount of the medicines actually purchased by the A platform on the GPO platform with the theoretical total purchase amount;
step three: receiving the calculated data through a data receiving module, and importing the data into a file system for processing;
step four: and the processed data is counted and called through a counting module.
2. The method for calculating the extent of price reduction and the amount saved in purchasing a pharmaceutical group according to claim 1, wherein: the matching of platform a drugs with GPO drugs is as follows:
matching the common names of the two platforms of medicines;
secondly, matching the platform A medicine and the GPO medicine with the same common name and the GPO medicine with the same catalog dosage form under the common name;
thirdly, matching the platform A medicine and the GPO medicine with the same common name and the same catalogue dosage form in quality level with the GPO medicine under the same common name and the same catalogue dosage form;
fourthly, matching the A platform medicine and the GPO medicine with the same common name, the same catalogue formulation and the same quality level, wherein the attributes comprise the varieties of sugar-free, musk and bezoar, and the A platform medicine and the GPO medicine are matched with the GPO medicine with the same common name, the same catalogue formulation and the same quality level;
fifthly, matching the large-capacity basic infusion in the same-generic-name same-catalogue medicament form and same-quality-level medicament of the A platform medicament and the GPO medicament with an injection containing a refill, a specially-filled and pre-filled type (pre-filled and sealed) injector packing material under the same-generic-name same-catalogue medicament form and same-quality-level packing material;
sixthly, matching the attributes of the A platform medicine and the GPO medicine, matching the packing material, and matching the A platform medicine and the GPO medicine in specification without considering the attributes and the packing material of the medicine with the same general name, the same catalogue dosage form and the same quality level;
seventhly, matching the attributes of the A platform medicine and the GPO medicine, matching packing materials, matching the medicines with the same general name, the same catalogue dosage form and the same quality level without considering the attributes and the packing materials, and matching small dosage forms after the medicines are matched with the GPO medicine in specification;
and eighthly, matching the attributes of the A platform medicine and the GPO medicine, matching the packaging material, and matching the medicine with the same general name, the same catalogue dosage form, the same quality level, the same specification and the same small dosage form without considering the attributes and the packaging material with the GPO medicine for the medicine production enterprises.
3. The method for calculating the purchase price reduction range and the saved amount of the pharmaceutical product group according to claim 2, wherein: the distinction between attributes with sugar and without sugar (sucrose only) is divided into different groups; the calculus bovis and Moschus contained in the composition are divided into three groups according to nature, cultivation (including in vitro cultivation), and artificial cultivation.
4. The method for calculating the purchase price reduction range and the saved amount of the pharmaceutical product group according to claim 2, wherein: the A platform medicines which can be matched with the same GPO medicine are regarded as the same group and correspond to the GPO medicine, and in the group matching process, the priority matching is carried out according to the following sequence: firstly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and the same production enterprises, and secondly, matching medicines with the same universal name, catalog dosage form, small dosage form and specification and different production enterprises; thirdly, matching medicines with the same universal name, the same catalog dosage form and the same specification and different small dosage forms; matching with medicines with the same general name, the same catalog dosage form and the same small dosage form and different specifications again; matching the medicines with the same universal name, the same catalog dosage form, different small dosage forms and different specifications.
5. The method for calculating the extent of price reduction and the amount saved in purchasing a pharmaceutical group according to claim 1, wherein: calculating the price reduction amplitude and the amount capable of being saved: before the online process, a Rad price index method is used for predicting the amplitude reduction and the amount of money saved of GPO if the medicine of the A platform is purchased on a GPO platform, and after the online process is finished, a Pascal price index method is used for measuring and calculating the actual amplitude reduction and the actual amount of money saved of the medicine purchased by the GPO.
6. The method of claim 5, wherein the method comprises the steps of: the said Laplace price index is an index taking the quantity of the basic period as the weight, the purchasing quantity of the same quantity is fixed in the basic period, and the change of the total sum is compared to reflect the change of the price.
7. The method of claim 5, wherein the method comprises the steps of: the Party price index is an index taking the amount in the report period as the weight, the purchase amount in the same amount is fixed in the report period, and the change of the total amount is compared to reflect the change condition of the price.
8. The method for calculating the extent of price reduction and the amount saved in purchasing a pharmaceutical group according to claim 1, wherein: the system further comprises a logic processing module, wherein the logic processing module is used for acquiring effective data according to the receiving condition of the data, and the effective data comprises: determining whether at least one of data loss and data duplication occurs.
9. The method for calculating the extent of price reduction and the amount saved in purchasing a pharmaceutical group according to claim 1, wherein: the file system updating system further comprises an updating module, and the updating module is used for updating the file system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110316200.8A CN112884530A (en) | 2021-03-24 | 2021-03-24 | Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110316200.8A CN112884530A (en) | 2021-03-24 | 2021-03-24 | Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112884530A true CN112884530A (en) | 2021-06-01 |
Family
ID=76042227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110316200.8A Pending CN112884530A (en) | 2021-03-24 | 2021-03-24 | Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112884530A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113313526A (en) * | 2021-06-07 | 2021-08-27 | 深圳市全药网科技有限公司 | Full-flow medicine price linkage monitoring system and intelligent system implementation method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105068994A (en) * | 2015-08-13 | 2015-11-18 | 易保互联医疗信息科技（北京）有限公司 | Natural language processing method and system for drug information |
| CN105139300A (en) * | 2015-08-18 | 2015-12-09 | 北京创聚数据科技有限责任公司 | Method for controlling catering supply chain cost based on big data analysis |
| CN108897809A (en) * | 2018-06-19 | 2018-11-27 | 中南大学湘雅医院 | Procurement information input system, method and device |
| CN109145192A (en) * | 2018-09-17 | 2019-01-04 | 珠海横琴盛达兆业科技投资有限公司 | A method of the automatic rate of exchange of drug are realized based on internet platform |
| CN109524125A (en) * | 2019-01-24 | 2019-03-26 | 易保互联医疗信息科技（北京）有限公司 | Drug stock analysis method, storage medium and equipment based on medical big data |
-
2021
- 2021-03-24 CN CN202110316200.8A patent/CN112884530A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105068994A (en) * | 2015-08-13 | 2015-11-18 | 易保互联医疗信息科技（北京）有限公司 | Natural language processing method and system for drug information |
| CN105139300A (en) * | 2015-08-18 | 2015-12-09 | 北京创聚数据科技有限责任公司 | Method for controlling catering supply chain cost based on big data analysis |
| CN108897809A (en) * | 2018-06-19 | 2018-11-27 | 中南大学湘雅医院 | Procurement information input system, method and device |
| CN109145192A (en) * | 2018-09-17 | 2019-01-04 | 珠海横琴盛达兆业科技投资有限公司 | A method of the automatic rate of exchange of drug are realized based on internet platform |
| CN109524125A (en) * | 2019-01-24 | 2019-03-26 | 易保互联医疗信息科技（北京）有限公司 | Drug stock analysis method, storage medium and equipment based on medical big data |
Non-Patent Citations (5)
| Title |
|---|
| "2009年浙江省国家基本药物集中采购实施方案", 《中国药房》, pages 695 - 699 * |
| 刘朝一: "基于价格指数的基本药物价格...—以江苏省抗感染类药物为例", 《卫生经济研究》, vol. 37, no. 8, pages 38 - 41 * |
| 吴晶: "中国药品价格和数量指数及偏倚的实证分析", 《中国药物经济学》, no. 1, pages 7 - 17 * |
| 杨燕 等: "深圳市药品集中采购对降低药品价格的效果分析", 《中国卫生资源》, vol. 22, no. 6, pages 445 - 448 * |
| 杨燕 等: "深圳市药品集中采购对降低药品费用的成效研究", 《中国卫生政策研究》, vol. 13, no. 1, pages 57 - 61 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113313526A (en) * | 2021-06-07 | 2021-08-27 | 深圳市全药网科技有限公司 | Full-flow medicine price linkage monitoring system and intelligent system implementation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foster | Supply and use of essential drugs in sub-Saharan Africa: some issues and possible solutions | |
| CN111599435B (en) | Intelligent pharmacy data processing method and device based on medical advice information | |
| CN113034104A (en) | Intelligent big data analysis method and system for medicine group purchasing | |
| US20190371477A1 (en) | Systems for making personalized medicine | |
| CN112884530A (en) | Method for measuring and calculating purchase price reduction amplitude and saved amount of medicine group | |
| US20160027136A1 (en) | Reference price index for pharmaceutical products | |
| US20110288883A1 (en) | Cooperative system and method of fulfilling prescriptions | |
| Neyaz et al. | Medication prescribing pattern in primary care in Riyadh City, Saudi Arabia | |
| KR20160111606A (en) | Process management method using process management system for preparing herbal medicine | |
| CN112863638A (en) | Internet hospital cloud pharmacy system and medicine distribution mode thereof | |
| Cocks et al. | Pricing behavior of the ethical pharmaceutical industry | |
| Schafheutle et al. | Non‐dispensing of NHS prescriptions in community pharmacies | |
| Balestrieri et al. | Antidepressant drug prescribing in general practice: a 6-year study | |
| Séné et al. | A general model of drug prescription | |
| CN113562208A (en) | Automatic sorting method and sorting system for traditional Chinese medicine decoction pieces | |
| Wongpoowarak et al. | Unused medications at home—reasons and costs | |
| Lansang et al. | A drugstore survey of antibiotic use in a rural community in the Philippines | |
| Ferguson et al. | The Nelson Prescribing Project: a programmed intervention in general practice in New Zealand | |
| Karamikhah et al. | Cost estimation related to drug waste in two major pediatric referral centers and one adult hospital in southern Iran: comparative cross-sectional study | |
| Martinez et al. | Medication management: A case of brown bag-identified medication hoarding | |
| You | Discussion on the application of tablet auto pack system | |
| Wu et al. | The Economic Benefits of Implementing a Quantity-Based Drug Procurement Policy in Zhejiang Province | |
| Shapovalov et al. | Organizational and legal aspects of the use of pharmacoeconomic analysis of multivitamin complexes for pharmaceutical provision of military personnel | |
| Luguzis et al. | The impact of prescribed dosage assumptions on the evaluation of adherence and persistence to medication in patients after acute myocardial infarction | |
| Wilcock | Dispensing doctors and non-dispensing doctors—A comparison of their prescribing costs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |